Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 32 clinical trials
featured
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous Investigational Product in Patients With Systemic Lupus Erythematosus (SLE)

A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous Investigational Product in Patients With Systemic Lupus Erythematosus (SLE)

  • 674 views
  • 08 Nov, 2020
  • 1 location
Efficacy of Immunoglobulin Plus Prednisolone in Reducing Coronary Artery Lesion in Patients With Kawasaki Disease

This study evaluates the efficacy of the addition of prednisolone to conventional initial treatment (intravenous immunoglobulin [IVIG] plus aspirin) in reducing coronary artery lesion in

fever
igiv
immunoglobulin
immune globulin
aspirin
  • 0 views
  • 20 Mar, 2021
  • 15 locations
Intravenous Immunoglobulin (IVIG) for Resistant Neuropathic Pain

that neuroinflammation appears to be involved in development and maintenance of neuropathic pain. This study explores the effects of an immune-modulating blood-derived product, intravenous

postherpetic neuralgia
analgesics
neuropathy
diabetic neuropathy
pain relief
  • 159 views
  • 07 Nov, 2020
  • 1 location
A Study of Imlifidase in Patients With Guillain-Barr Syndrome

The study participants are patients which have been diagnosed with Guillain-Barr Syndrome (GBS) and are planned to receive treatment with intravenous immunoglobulin (IVIg). IVIg is a standard of

  • 18 views
  • 21 Apr, 2021
  • 15 locations
Efficacy and Safety of Immunoglobulin Associated With Rituximab Versus Rituximab Alone in Childhood-Onset Steroid-dependent Nephrotic Syndrome

remission rate after 2 years is only 30 to 40%. The aim of the study is to study the ability of intravenous Immunoglobulin to improve remission rate in SDNS when added associated with Rituximab

  • 20 views
  • 24 Jan, 2021
  • 1 location
IVIg Therapy for Patients With Idiopathic Cardiomyopathy and Endomyocardial Biopsy Proven High PVB19 Viral Load

of intravenous immunoglobulin (IVIg) in addition to conventional heart failure therapy achieves virus reduction, thereby resulting in improvement of cardiac function. Study design: A

cardiomyopathy
ejection fraction
  • 23 views
  • 07 Nov, 2020
  • 1 location
Randomised Evaluation of COVID-19 Therapy

RECOVERY is a randomised trial investigating whether treatment with Lopinavir-Ritonavir, Hydroxychloroquine, Corticosteroids, Azithromycin, Colchicine, IV Immunoglobulin (children only), Convalescent plasma, Synthetic neutralizing antibodies (REGN-COV2), Tocilizumab, Aspirin, Baricitinib, Infliximab or Anakinra (children only) prevents death in patients with COVID-19.

pneumonia
corticosteroids
lopinavir
covid-19
ritonavir
  • 0 views
  • 13 May, 2021
  • 3 locations
Infliximab and Intravenous Immunoglobulin Therapy in Treating Patients With Steroid-Refractory Pneumonitis

This phase II trial studies how well infliximab and intravenous immunoglobulin therapy work in treating patients with pneumonitis that does not respond to steroid treatment. Immunotherapy with

antibiotics
antibody therapy
monoclonal antibodies
solid tumor
corticosteroids
  • 0 views
  • 14 May, 2021
  • 2 locations
The Efficacy Of Intravenous Immunoglobulin Therapy In Treatment Induced Neuropathy Of Diabetes

The goal of this pilot study is to obtain preliminary data on the magnitude of the treatment effect of IVIG on the neuropathic pain and neuropathy severity associated with treatment induced neuropathy (TIND). The investigators hypothesize that immune globulin, administered intravenously (IVIG), will reduce the pain associated with treatment induced …

hemoglobin a1c
electrocardiogram
neuralgia
diabetic polyneuropathy
autonomic neuropathy
  • 398 views
  • 25 Jan, 2021
  • 1 location
rATG Versus rATG Combined With Intravenous Immunoglobulin (IVIG) Induction Immunosuppression in HLA Incompatible Transplantation (INHIBIT)

This study aims to prove similar efficacy of PE/rATG (intervention) and PE/rATG/IVIG (centre standard of care) induction regimens to prevent biopsy proven antibody-mediated changes and TCMR as composite endpoint within 12 months after HLA incompatible kidney transplantation.

  • 0 views
  • 13 Apr, 2021
  • 1 location